Xeomin 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FM39D
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $50,429
Award facts
- Contract value 100% obligated
- $50,428.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $50,428.56 to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of Xeomin 200 Unit Vials, with an ultimate completion date of February 4, 2026. This firm fixed-price contract was awarded on a competitive basis with no set-aside designation. The product will be delivered to a facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a significant Indefinite Delivery Contract with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031, serving as the comprehensive vehicle for pharmaceutical and medical supply deliveries to military healthcare programs worldwide.
Xeomin (incobotulinumtoxinA) is a botulinum toxin product used in therapeutic and cosmetic medical applications, and its procurement through the DLA supply chain reflects the federal military healthcare system's need for specialized pharmaceutical products across multiple therapeutic domains. This award demonstrates AmerisourceBergen's continued capability to fulfill federal medical procurement requirements as a major pharmaceutical distributor serving Defense Health Agency and military treatment facilities globally. The delivery order structure allows for efficient procurement of specific pharmaceutical commodities while leveraging the parent company's broader IDC framework with DLA.
Quick answers
Who was awarded contract SPE2DR26FM39D?
SPE2DR26FM39D was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FM39D worth?
The government has obligated $50,429 on SPE2DR26FM39D.
Is contract SPE2DR26FM39D an order under another contract?
Yes. SPE2DR26FM39D is a delivery order under SPE2DR25D2007, an indefinite delivery contract.
Was contract SPE2DR26FM39D competed?
The extent of competition for SPE2DR26FM39D was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award